Open Access

Anti‑inflammatory effects of glycine thymosin β4 eye drops in experimental dry eye

  • Authors:
    • Rujun Jin
    • Ying Li
    • Lan Li
    • Dong Hwan Kim
    • Che Dong Yang
    • Han Sun Son
    • Jung Han Choi
    • Hyeon Jeong Yoon
    • Kyung Chul Yoon
  • View Affiliations

  • Published online on: April 2, 2020     https://doi.org/10.3892/br.2020.1296
  • Pages: 319-325
  • Copyright: © Jin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to investigate the anti-inflammatory effects of glycine thymosin β4 (Gly-Tβ4) eye drops, and to compare the efficacy of topical Gly‑Tβ4 with Cyclosporine A (CsA) in a mouse model of experimental dry eye (EDE). Eye drops consisting of balanced salt solution (BSS), 0.1% Gly‑Tβ4 or 0.05% CsA were used for treatment of EDE. Tear volume, tear film break‑up time and corneal staining scores were measured after 7 and 14 days. Periodic acid‑Schiff staining for conjunctival gobleT cells, TUNEL assay for corneal apoptotic positive cells, multiplex immunobead assay for interleukin (IL)‑1β, IL‑6, tumor necrosis factor‑α and interferon‑γ levels, and flow cytometry for CD4+/CCR5+ T cells were performed after 14 days. All clinical parameters showed improvement in the Gly‑Tβ4 and CsA groups (all P<0.05). Significantly increased conjunctival gobleT cells and decreased corneal TUNEL positive cells were observed in the Gly‑Tβ4 and CsA groups. The Gly‑Tβ4 and CsA treated groups showed significantly reduced inflammatory cytokine levels and T cells in the conjunctiva compared with the EDE and BSS groups (all P<0.05). However, there were no significant differences observed in the inflammatory and clinical parameters between the Gly‑Tβ4 and CsA treatment groups. Topical application of 0.1% Gly‑Tβ4 significantly reduced inflammation on the ocular surface, as well as clinical parameters of EDE, with a similar efficacy to that of 0.05% CsA emulsions, suggesting that Gly‑Tβ4 eye drops may be used as a therapeutic agent for treatment of dry eye disease.
View Figures
View References

Related Articles

Journal Cover

June-2020
Volume 12 Issue 6

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Jin R, Li Y, Li L, Kim D, Yang C, Son H, Choi J, Yoon H and Yoon K: Anti‑inflammatory effects of glycine thymosin β4 eye drops in experimental dry eye. Biomed Rep 12: 319-325, 2020.
APA
Jin, R., Li, Y., Li, L., Kim, D., Yang, C., Son, H. ... Yoon, K. (2020). Anti‑inflammatory effects of glycine thymosin β4 eye drops in experimental dry eye. Biomedical Reports, 12, 319-325. https://doi.org/10.3892/br.2020.1296
MLA
Jin, R., Li, Y., Li, L., Kim, D., Yang, C., Son, H., Choi, J., Yoon, H., Yoon, K."Anti‑inflammatory effects of glycine thymosin β4 eye drops in experimental dry eye". Biomedical Reports 12.6 (2020): 319-325.
Chicago
Jin, R., Li, Y., Li, L., Kim, D., Yang, C., Son, H., Choi, J., Yoon, H., Yoon, K."Anti‑inflammatory effects of glycine thymosin β4 eye drops in experimental dry eye". Biomedical Reports 12, no. 6 (2020): 319-325. https://doi.org/10.3892/br.2020.1296